Skip to main content
. Author manuscript; available in PMC: 2020 Sep 15.
Published in final edited form as: Bioorg Med Chem Lett. 2019 Jul 10;29(18):2695–2699. doi: 10.1016/j.bmcl.2019.07.012

Table 1.

Results of clinical inhibitors.

Compound/μM Mtb signala WS-1b
1.25 2.5 5 10 20 (μM)
Gefitinib 1.08 1.09 1.05 1.08 1.05 23
Erlotinib 1.05 0.96 0.9 0.68 0.7 8.6
Lapatinib 0.99 0.9 0.74 0.17 0.08 13
a

Relative luminescence measured at 3 days after treatment. Values = RLU(sample)/RLU(no compound) at μM concentrations and no effect at 0.625 μM;

b

ref11